Fetale und neonatale Alloimmunthrombozytopenie

Ulrich J. Sachs; Ivonne Bedei; Sandra Wienzek-Lischka; Nina Cooper; Harald Ehrhardt; Roland Axt-Fliedner; Gregor Bein

doi:10.1055/a-2421-7703

Neonatologie Scan, Inhaltsverzeichnis

Neonatologie Scan 2025; 14(01): 69-87
DOI: 10.1055/a-2421-7703

CME-Fortbildung

Fetale und neonatale Alloimmunthrombozytopenie

Ulrich J. Sachs

,

Ivonne Bedei

,

Sandra Wienzek-Lischka

,

Nina Cooper

,

Harald Ehrhardt

,

Roland Axt-Fliedner

,

Gregor Bein

Abstract

Mütterliche Antikörper, die gegen ein vom Vater ererbtes Blutgruppenmerkmal an fetalen Thrombozyten gerichtet sind, können eine fetale oder neonatale Alloimmunthrombozytopenie (FNAIT) hervorrufen. Durch eine frühzeitige Erkennung und Behandlung dieser Erkrankung können schwerwiegende Komplikationen bei den betroffenen Feten oder Neugeborenen sowie in einer Folgeschwangerschaft verhindert werden.

Schlüsselwörter

Neonatologie - FNAIT - fetale Alloimmunthrobozytopathie - neonatale Alloimmunthrobozytopathie - intrakraniale Hämorrhagie - ICH - fetale Hirnblutung

Volltext

Referenzen

Literatur
1 Tiller H, Kamphuis MM, Flodmark O. et al. Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open 2013; 3
2 Kamphuis MM, Paridaans NP, Porcelijn L. et al. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics 2014; 133: 715-721
3 Kamphuis MM, Paridaans N, Porcelijn L. et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 2010; 117: 1335-1343
4 Vos TW de, Winkelhorst D, Porcelijn L. et al. Natural history of human platelet antigen 1a-alloimmunised pregnancies: a prospective observational cohort study. Lancet Haematol 2023; 10: e985-e993
5 Davoren A, McParland P, Barnes CA. et al. Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol 2002; 55: 289-292
6 Sachs UJ, Wienzek-Lischka S, Duong Y. et al. Maternal antibodies against paternal class I human leukocyte antigens are not associated with foetal and neonatal alloimmune thrombocytopenia. Br J Haematol 2020; 189: 751-759
7 Versiti. HPA Database (2024). Zugriff am 05. November 2024 unter: www.versiti.org/hpa
8 Sachs UJ, Bedei I, Wienzek-Lischka S. et al. Fetale und neonatale Alloimmunthrombozytopenie, Teil 1. Transfusionsmedizin 2021; 11: 112-126
9 Mueller-Eckhardt C, Kiefel V, Grubert A. et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989; 1: 363-366
10 Jin JC, Lakkaraja MM, Ferd P. et al. Maternal sensitization occurs before delivery in severe cases of fetal alloimmune thrombocytopenia. Am J Hematol 2019; 94: E213-E215
11 Kjeldsen-Kragh J, Ahlen MT. Foetal and neonatal alloimmune thrombocytopenia – The role of the HLA-DRB3*01:01 allele for HPA-1a-immunisation and foetal/neonatal outcome. Transfus Apher Sci 2020; 59: 102707
12 Wienzek-Lischka S, König IR, Papenkort EM. et al. HLA-DRB3*01:01 is a predictor of immunization against human platelet antigen-1a but not of the severity of fetal and neonatal alloimmune thrombocytopenia. Transfusion 2017; 57: 533-540
13 Pyzik M, Kozicky LK, Gandhi AK. et al. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol 2023; 23: 415-432
14 Palmeira P, Quinello C, Silveira-Lessa AL. et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012: 985646
15 Santoso S, Wihadmadyatami H, Bakchoul T. et al. Antiendothelial αvβ3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia. Arterioscler Thromb Vasc Biol 2016; 36: 1517-1524
16 Alm J, Duong Y, Wienzek-Lischka S. et al. Anti-human platelet antigen-5b antibodies and fetal and neonatal alloimmune thrombocytopenia; incidental association or cause and effect?. Br J Haematol 2022; 198: 14-23
17 Miserre L, Wienzek-Lischka S, Mann A. et al. ABO Incompatibility between the Mother and Fetus Does Not Protect against Anti-Human Platelet Antigen-1a Immunization by Pregnancy. J Clin Med 2022; 11: 6811
18 Vos TW de, Porcelijn L, Hofstede-van Egmond S. et al. Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia. Br J Haematol 2021; 195: 595-603
19 Ghevaert C, Campbell K, Walton J. et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 2007; 47: 901-910
20 Tiller H, Killie MK, Husebekk A. et al. Platelet antibodies and fetal growth: maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys. Acta Obstet Gynecol Scand 2012; 91: 79-86
21 Bussel JB, Zacharoulis S, Kramer K. et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005; 45: 176-183
22 Winkelhorst D, Kamphuis MM, Steggerda SJ. et al. Perinatal Outcome and Long-Term Neurodevelopment after Intracranial Haemorrhage due to Fetal and Neonatal Alloimmune Thrombocytopenia. Fetal Diagn Ther 2019; 45: 184-191
23 Radder CM, Brand A, Kanhai HHH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang 2003; 84: 318-325
24 Vos TW de, van Zagten M, Haas M de. et al. Children Newly Diagnosed with Fetal and Neonatal Alloimmune Thrombocytopenia: Neurodevelopmental Outcome at School Age. J Pediatr 2023; 258: 113385
25 Vos TW de, Winkelhorst D, Baelde HJ. et al. Placental Complement Activation in Fetal and Neonatal Alloimmune Thrombocytopenia: An Observational Study. IJMS 2021; 22: 6763
26 Dubruc E, Lebreton F, Giannoli C. et al. Placental histological lesions in fetal and neonatal alloimmune thrombocytopenia: A retrospective cohort study of 21 cases. Placenta 2016; 48: 104-109
27 Böhm D, Wienzek-Lischka S, Cooper N. et al. Fetal and neonatal alloimmune thrombocytopenia: No evidence of systemic inflammation as a modulator of disease severity. Could placental inflammation be key?. Br J Haematol 2023; 203: 304-310
28 Kiefel V, Santoso S, Weisheit M. et al. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-1726
29 Porcelijn L, Huiskes E, Comijs-van Osselen I. et al. A new bead-based human platelet antigen antibodies detection assay versus the monoclonal antibody immobilization of platelet antigens assay. Transfusion 2014; 54: 1486-1492
30 Cooper N, Bein G, Heidinger K. et al. A bead-based assay in the work-up of suspected platelet alloimmunization. Transfusion 2016; 56: 115-118
31 Kroll H, Yates J, Santoso S. Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion 2005; 45: 353-358
32 Holzwarth ST, Strobel J, Cooper N. et al. A point mutation c.473A G of ITGB3 is responsible for the formation of the Woa human platelet alloantigen. Transfusion 2020; 60: E5-E6
33 Petermann R, Bakchoul T, Curtis BR. et al. Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16: 2526-2529
34 Bakchoul T, Kubiak S, Krautwurst A. et al. Low-avidity anti-HPA-1a alloantibodies are capable of antigen-positive platelet destruction in the NOD/SCID mouse model of alloimmune thrombocytopenia. Transfusion 2011; 51: 2455-2461
35 Peterson JA, Kanack A, Nayak D. et al. Prevalence and clinical significance of low-avidity HPA-1a antibodies in women exposed to HPA-1a during pregnancy. Transfusion 2013; 53: 1309-1318
36 Tiller H, Husebekk A, Skogen B. et al. True risk of fetal/neonatal alloimmune thrombocytopenia in subsequent pregnancies: a prospective observational follow-up study. BJOG 2016; 123: 738-744
37 Ernstsen SL, Ahlen MT, Johansen T. et al. Antenatal intravenous immunoglobulins in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia: comparison of neonatal outcome in treated and nontreated pregnancies. Am J Obstet Gynecol 2022; 227: 506.e1-506.e12
38 Knightly KA, Bussel JB, McKelvy M. et al. Does absence of intracranial hemorrhage in the first pregnancy in fetal and neonatal alloimmune thrombocytopenia preclude occurrence in the second?. Am J Hematol 2024; 99: 468-472
39 Bussel JB, Berkowitz RL, Hung C. et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol 2010; 203: 135
40 Sachs UJ. Prospects for risk stratification of anti-HPA-1a alloimmunized pregnant women. Transfus Apher Sci 2020; 59: 102709
41 Kapur R, Kustiawan I, Vestrheim A. et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 2014; 123: 471-480
42 Sonneveld ME, Natunen S, Sainio S. et al. Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia. Br J Haematol 2016; 174: 310-320
43 Kjaer M, Bertrand G, Bakchoul T. et al. Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. Vox Sanguinis 2019; 114: 79-94
44 Scheffer PG, Ait Soussan A, Verhagen O. et al. Noninvasive fetal genotyping of human platelet antigen-1a. BJOG 2011; 118: 1392-1395
45 Wienzek-Lischka S, Bachmann S, Froehner V. et al. Potential of Next-Generation Sequencing in Noninvasive Fetal Molecular Blood Group Genotyping. Transfus Med Hemother 2020; 47: 14-22
46 Moise KJ, Carpenter RJ. Increased severity of fetal hemolytic disease with known rhesus alloimmunization after first-trimester transcervical chorionic villus biopsy. Fetal Diagn Ther 1990; 5: 76-78
47 Axt-Fliedner R, Wienzek-Lischka S, Sachs UJ. et al. Hämolytische Erkrankung des Fetus und Neugeborenen. Transfusionsmedizin 2018; 8: 95-110
48 Regan F, Lees CC, Jones B. et al. Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT): Scientific Impact Paper No. 61. BJOG 2019; 126: e173-e185
49 Refsum E, Håkansson S, Mörtberg A. et al. Intracranial hemorrhages in neonates born from 32 weeks of gestation-low frequency of associated fetal and neonatal alloimmune thrombocytopenia: a register-based study. Transfusion 2018; 58: 223-231
50 Coste T, Vincent-Delorme C, Stichelbout M. et al. COL4A1/COL4A2 and inherited platelet disorder gene variants in fetuses showing intracranial hemorrhage. Prenat Diagn 2022; 42: 601-610
51 Girard N, Chaumoitre K, Confort-Gouny S. et al. Magnetic resonance imaging and the detection of fetal brain anomalies, injury, and physiologic adaptations. Curr Opin Obstet Gynecol 2006; 18: 164-176
52 Daffos F, Forestier F, Muller JY. et al. Prenatal treatment of alloimmune thrombocytopenia. Lancet 1984; 2: 632
53 Paidas MJ, Berkowitz RL, Lynch L. et al. Alloimmune thrombocytopenia: Fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995; 172: 475-479
54 Overton TG, Duncan KR, Jolly M. et al. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol 2002; 186: 826-831
55 Bussel JB, Berkowitz RL, McFarland JG. et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988; 319: 1374-1378
56 Winkelhorst D, Murphy MF, Greinacher A. et al. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. A systematic review. Blood 2017; 129: 1538-1547
57 Lieberman L, Greinacher A, Murphy MF. et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. Br J Haematol 2019; 185: 549-562
58 Bundesärztekammer. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Gesamtnovelle 2020. https://www.wbbaek.de/fileadmin/user_upload/_old-files/downloads/pdf-Ordner/MuE/Querschnitts-Leitlinien_BAEK_zur_Therapie_mit_Blutkomponenten_und_Plasmaderivaten-Gesamtnovelle_2020.pdf
59 Kjeldsen-Kragh J, Bein G, Tiller H. Pregnant Women at Low Risk of Having a Child with Fetal and Neonatal Alloimmune Thrombocytopenia Do Not Require Treatment with Intravenous Immunoglobulin. J Clin Med 2023; 12
60 Wienzek-Lischka S, Sawazki A, Ehrhardt H. et al. Non-invasive risk-assessment and bleeding prophylaxis with IVIG in pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia: management to minimize adverse events. Arch Gynecol Obstet 2020; 302: 355-363
61 Herrmann A, Samelson-Jones BJ, Brake S. et al. IVIG-Associated Maternal Pancytopenia during Treatment for Neonatal Alloimmune Thrombocytopenia. AJP Rep 2017; 7: e197-e200
62 de Vos TW, de Haas M, Oepkes D. et al. Long-term neurodevelopmental outcome in children after antenatal intravenous immune globulin treatment in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2022; 227: 637.e1-637.e9
63 van den Akker ES, Oepkes D, Brand A. et al. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia?. BJOG 2006; 113: 781-783
64 Vos TW de, Winkelhorst D, Haas M de. et al. Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia. Transfus Apher Sci 2020; 59: 102704
65 Tiller H, Ahlen MT, Akkök ÇA. et al. Fetal and neonatal alloimmune thrombocytopenia – The Norwegian management model. Transfus Apher Sci 2020; 59: 102711
66 Sachs UJ, Bedei I, Wienzek-Lischka S. et al. Fetale und neonatale Alloimmunthrombozytopenie, Teil 2. Transfusionsmedizin 2021; 11: 127-142
67 Dame C. Neonatale Thrombozytopenie. Monatsschr Kinderheilkd 2018; 166: 959-967
68 Stanworth SJ, Mumford AD. How I diagnose and treat neonatal thrombocytopenia. Blood 2023; 141: 2685-2697
69 Winkelhorst D, Kamphuis MM, Kloet LC de. et al. Severe bleeding complications other than intracranial hemorrhage in neonatal alloimmune thrombocytopenia: a case series and review of the literature. Transfusion 2016; 56: 1230-1235
70 Kovanlikaya A, Tiwari P, Bussel JB. Imaging and management of fetuses and neonates with alloimmune thrombocytopenia. Pediatr Blood Cancer 2017; 64
71 Sparger KA, Assmann SF, Granger S. et al. Platelet Transfusion Practices Among Very-Low-Birth-Weight Infants. JAMA Pediatr 2016; 170: 687-694
72 Curley A, Stanworth SJ, Willoughby K. et al. Randomized Trial of Platelet-Transfusion Thresholds in Neonates. N Engl J Med 2019; 380: 242-251
73 Fustolo-Gunnink SF, Fijnvandraat K, van Klaveren D. et al. Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. Blood 2019; 134: 2354-2360
74 Baker JM, Shehata N, Bussel J. et al. Postnatal intervention for the treatment of FNAIT: a systematic review. J Perinatol 2019; 39: 1329-1339
75 Vos TW de, Winkelhorst D, Árnadóttir V. et al. Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study. Lancet Haematol 2022; 9: e844-e853
76 Chakravorty S, Roberts I. How I manage neonatal thrombocytopenia. Br J Haematol 2012; 156: 155-162
77 Kjeldsen-Kragh J, Killie MK, Tomter G. et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007; 110: 833-839
78 Kjær M, Geisen C, Akkök ÇA. et al. Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia. Transfus Apher Sci 2020; 59: 102712
79 Geisen C, Kjaer M, Fleck E. et al. An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study. J Thromb Haemost 2023; 21: 838-849
80 Moise KJ, Ling LE, Oepkes D. et al. Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn. New Engl J Med 2024; 391: 526-537